公开(公告)号：US07189800B2

公开(公告)日：2007-03-13

申请号：US10105232

申请日：2002-03-26

Applicant: Samuel Bogoch ,  Elenore S. Bogoch

Inventor： Samuel Bogoch ,  Elenore S. Bogoch

IPC: C07K14/11 ,  C07K4/02

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/53 ,  C07K14/195 ,  C07K14/205 ,  C07K14/21 ,  C07K14/22 ,  C07K14/24 ,  C07K14/245 ,  C07K14/255 ,  C07K14/26 ,  C07K14/27 ,  C07K14/28 ,  C07K14/285 ,  C07K14/30 ,  C07K14/305 ,  C07K14/31 ,  C07K14/315 ,  C07K14/32 ,  C07K14/33 ,  C07K14/335 ,  C07K14/34 ,  C07K14/345 ,  C07K14/35 ,  C07K14/355 ,  C07K14/36 ,  C07K14/37 ,  C07K14/38 ,  C07K14/385 ,  C07K14/39 ,  C07K14/40 ,  C07K14/405 ,  C07K14/415 ,  C07K14/44 ,  C07K14/445 ,  C07K14/47 ,  C12N2710/24122 ,  C12N2760/16022 ,  C12N2760/16122 ,  Y02A50/412

Abstract: Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.

Abstract translation: 公开了流感病毒血凝素蛋白和恶性疟原虫疟疾抗原肽，肽特异性抗体，流感疫苗，疟疾疫苗和刺激受试者的免疫应答以产生抗流感病毒或疟疾的方法。 还公开了用于制定用于流感病毒的疫苗的方法。

公开(公告)号：US20020123457A1

公开(公告)日：2002-09-05

申请号：US09381261

申请日：1999-12-07

Inventor： JOSEPH LOSCALZO ,  AIDA INBAL

IPC: A01N037/18 ,  A61K038/00 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K007/00 ,  C07K014/00 ,  C07K016/00 ,  C07K017/00

CPC classification number: C07K14/355 ,  A61K38/00

Abstract: This invention combines the unique antiplatelet effects of S-nitrosothiols and the antiadhesive properties of fragments of vWF in the A1 domain to provide unique molecules that exploit both of these properties. Preferred molecules comprise a fragment of A1 (ala444-asp73O) in which arginine at position 545 is replaced by cysteine (the most frequent von Willebrand disease type 2b mutation) that has been discovered to impair platelet adhesion, and to exhibit antithrombotic activity in vivo. This cysteine residue may be S-nitrosated to produce a novel molecule that has the potential for impairing platelet adhesion as well as activation/aggregation, and such molecules form the basis of a novel therapeutic method for impairing platelet responses following vascular injury or in other thrombotic disorders according to this invention.

Abstract translation: 本发明将S-亚硝基硫醇的独特抗血小板作用和vWF片段的抗粘附性质结合在A1结构域中，以提供利用这两种特性的独特分子。 优选的分子包含A1（ala444-asp73O）的片段，其中545处的精氨酸被已被发现损伤血小板粘附的半胱氨酸（最常见的血管性血友病血型B型突变）所代替，并在体内表现出抗血栓形成活性。 该半胱氨酸残基可以被S-亚硝基化以产生具有损害血小板粘附和活化/聚集的潜力的新分子，并且这些分子形成用于损伤血管损伤或其它血栓形成后血小板反应的新型治疗方法的基础 根据本发明的病症。